Nectar Lifesciences Limited

rs,

Sub: Investor Presentation (Q3’FY25) 2. BSE Limited Corporate Relationship Department, P J Towers, Dalal Street, Mumbai 400 001 Scrip Code: 532649 Ref: Disclosure under Regulation 30 of Securitie

₹ 454.33 Crore

l Performance Period Revenue from Operations (Net of GST) EBITDA Profit After Tax Q3 FY 2025 ₹ 454.33 Crores (0.48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2

0.48%

riod Revenue from Operations (Net of GST) EBITDA Profit After Tax Q3 FY 2025 ₹ 454.33 Crores (0.48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 4

₹ 45.28 Crore

Operations (Net of GST) EBITDA Profit After Tax Q3 FY 2025 ₹ 454.33 Crores (0.48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crore

6.12%

of GST) EBITDA Profit After Tax Q3 FY 2025 ₹ 454.33 Crores (0.48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%

₹ 7.84 Crore

rofit After Tax Q3 FY 2025 ₹ 454.33 Crores (0.48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%)

399.36%

Q3 FY 2025 ₹ 454.33 Crores (0.48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24

₹ 452.17 Crore

48% YoY growth) ₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24 ₹ 1,684.09 Crores ₹ 166.14 Crores (9.

₹ 42.67 Crore

₹ 45.28 Crores (6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24 ₹ 1,684.09 Crores ₹ 166.14 Crores (9.87%) ₹ 5.00 Cro

9.44%

6.12% YoY Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24 ₹ 1,684.09 Crores ₹ 166.14 Crores (9.87%) ₹ 5.00 Crores (0.3

₹ 1.57 Crore

Y Growth) ₹ 7.84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24 ₹ 1,684.09 Crores ₹ 166.14 Crores (9.87%) ₹ 5.00 Crores (0.30%) ABOUT OUR

0.35%

84 Crores (399.36% YoY Growth) Q3 FY 2024 ₹ 452.17 Crores ₹ 42.67 Crores (9.44%) ₹ 1.57 Crores (0.35%) FY 2023-24 ₹ 1,684.09 Crores ₹ 166.14 Crores (9.87%) ₹ 5.00 Crores (0.30%) ABOUT OUR BUSINESS

“20% FY28 5% FY24 In-house API consumption Reduction of Long Term Debt ❖ Currently the company in Corporate Debt Restructuring(CDR) and WCTL Rs.61.90 Crs.”

“❖ On track to exit Corporate Debt Restructuring (CDR) by Jun.2026 and achieving lower interest rates and bank charges is expected to enhance profitability.”

“Financial Outlook: EBITDA margins expected to expand by 100-150 bps annually, with projected EBITDA of ₹175-185 crore in FY25 and ₹240-260 crore in FY26.”

“Revenue Growth: Targeting 7-10% revenue growth in FY26 and scaling formulations business sales to ₹600 crore+ by FY28.”

“Debt-Free by FY26: Long-term debt to be fully repaid by FY26, reducing interest costs and enhancing profitability at the PAT level.”

Regulated Markets driven by

1

Regulated Markets driven by

● Strong demand from CIS, LATAM, ASIA, AFRICA ● Cephalosporins have clearly demonstrated Non Resistant AMR properties because of which 2nd, 3rd and 4th generation cephalosporins are gaining momentum and traction globally. GLOBAL MANUFACTURING FACILITIES 29 years of Manufacturing Excellence Facilities Location Activity API Manufacturing Unit I Derabassi, Punjab Oral & Sterile Cephalosporin APIs API Manufacturing Unit II Derabassi, Punjab Oral & Sterile Cephalosporin APIs Formulation Manufacturing Unit Barotiwala, HP Cephalosporin FDFs - Oral & Injectables Capsule Manufacturing Unit Barotiwala, HP Empty Hard Gelatin Capsule Manufacturing Nectar API Global Business Presence Nectar FDF Global Business Presence Diversified Revenue Base FY24 API Business Split FDF Business Split API Domestic API Exports Formulation Exports Formulation Domestic 60% 40% 72% 28% Strong presence in API and formulation business in nearly 45 countries. Business Performance ○ ○ ○ Steady revenue growth despite indus